Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Study Evaluating the Role of Axumin (Fluciclovine or 18F-FACBC) PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Next Previous
Trial Profile

Prospective Study Evaluating the Role of Axumin (Fluciclovine or 18F-FACBC) PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms REFINE

Most Recent Events

  • 19 May 2026 According to a Blue Earth Diagnostics media release, data from this study will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, held from May 30-June 2, in Los Angeles, CA.
  • 14 Nov 2025 Planned End Date changed from 1 Jan 2026 to 1 Dec 2026.
  • 14 Nov 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top